Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BVS Bioventus	$8.33 -9.0%	$9.97	$3.90 ▼ $14.38	$682.59M	0.86	434,805 shs	350,720 shs
ENOV Enovis	$32.52 -3.8%	$40.90	$31.00 ▼ $62.79	$1.85B	2.05	717,915 shs	1.49 million shs
NVST Envista	$15.47 -3.9%	$19.18	$14.77 ▼ $23.00	$2.66B	1.12	2.45 million shs	5.80 million shs
TMDX TransMedics Group	$67.67 -4.6%	$70.07	$55.00 ▼ $177.37	$2.28B	2.14	1.32 million shs	1.38 million shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BVS Bioventus	-8.96%	-7.75%	-18.25%	-20.21%	+65.94%
ENOV Enovis	-3.63%	-13.83%	-13.53%	-24.84%	-45.16%
NVST Envista	-3.88%	-8.81%	-15.35%	-18.71%	-23.57%
TMDX TransMedics Group	-4.64%	-1.33%	+0.34%	-2.06%	-10.19%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BVS Bioventus	3.0446 of 5 stars	3.3	0.0	0.0	2.5	4.2	1.3
ENOV Enovis	2.9887 of 5 stars	3.4	3.0	0.0	2.5	1.7	1.9
NVST Envista	4.6709 of 5 stars	4.0	4.0	3.9	3.6	0.0	2.5
TMDX TransMedics Group	2.4135 of 5 stars	3.4	1.0	0.0	2.3	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BVS Bioventus	2.67	Moderate Buy	$15.00	80.07% Upside
ENOV Enovis	2.75	Moderate Buy	$58.50	79.89% Upside
NVST Envista	2.07	Hold	$20.18	30.44% Upside
TMDX TransMedics Group	2.82	Moderate Buy	$122.70	81.32% Upside

Current Analyst Ratings Breakdown

Latest BVS, NVST, TMDX, and ENOV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/2/2025	ENOV Enovis	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$64.00 ➝ $64.00
3/26/2025	TMDX TransMedics Group	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
3/17/2025	BVS Bioventus	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
3/11/2025	TMDX TransMedics Group	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$104.00 ➝ $104.00
3/10/2025	NVST Envista	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$23.00 ➝ $21.00
3/8/2025	NVST Envista	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$19.00
3/6/2025	NVST Envista	New Street Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$19.00
3/6/2025	NVST Envista	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$20.00 ➝ $19.00
3/6/2025	NVST Envista	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$20.00 ➝ $19.00
3/6/2025	NVST Envista	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
2/27/2025	ENOV Enovis	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$65.00 ➝ $64.00

(Data available from 4/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BVS Bioventus	$573.28M	1.19	$0.66 per share	12.58	$2.80 per share	2.98
ENOV Enovis	$2.11B	0.88	$4.74 per share	6.86	$62.66 per share	0.52
NVST Envista	$2.51B	1.06	$1.20 per share	12.91	$17.04 per share	0.91
TMDX TransMedics Group	$441.54M	5.16	$0.13 per share	530.08	$4.20 per share	16.11

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BVS Bioventus	-$156.23M	-$0.51	N/A	18.11	N/A	-7.11%	15.61%	4.01%	N/A
ENOV Enovis	-$33.26M	-$14.29	N/A	10.19	N/A	-5.95%	4.39%	2.80%	5/1/2025 (Estimated)
NVST Envista	-$1.12B	-$6.49	N/A	12.79	1.27	-44.56%	3.86%	2.21%	4/29/2025 (Estimated)
TMDX TransMedics Group	-$25.03M	$1.01	71.99	47.32	N/A	8.14%	18.74%	4.39%	4/29/2025 (Estimated)

Latest BVS, NVST, TMDX, and ENOV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/1/2025	N/A	ENOV Enovis	$0.74	N/A	N/A	N/A	$558.80 million	N/A
4/29/2025	N/A	TMDX TransMedics Group	$0.29	N/A	N/A	N/A	$123.39 million	N/A
2/26/2025	Q4 2024	ENOV Enovis	$0.92	$0.98	+$0.06	-$12.05	$555.14 million	$560.98 million
2/5/2025	Q4 2024	NVST Envista	$0.23	$0.24	+$0.01	$0.01	$646.28 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BVS Bioventus	N/A	N/A	N/A	N/A	N/A
ENOV Enovis	N/A	N/A	N/A	N/A	N/A
NVST Envista	N/A	N/A	N/A	N/A	N/A
TMDX TransMedics Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BVS Bioventus	1.85	1.41	0.99
ENOV Enovis	0.40	2.27	1.12
NVST Envista	0.44	2.04	1.76
TMDX TransMedics Group	2.42	8.20	7.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BVS Bioventus	62.94%
ENOV Enovis	98.45%
NVST Envista	N/A
TMDX TransMedics Group	99.67%

Insider Ownership

Company	Insider Ownership
BVS Bioventus	32.90%
ENOV Enovis	2.40%
NVST Envista	1.30%
TMDX TransMedics Group	7.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BVS Bioventus	1,200	81.94 million	54.46 million	Not Optionable
ENOV Enovis	6,800	56.96 million	55.49 million	Optionable
NVST Envista	12,700	172.19 million	169.95 million	Optionable
TMDX TransMedics Group	210	33.66 million	31.21 million	Optionable

BVS, NVST, TMDX, and ENOV Headlines

Recent News About These Companies

TMDX DEADLINE NOTICE: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages TransMedics Group, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 15 Deadline in Securities Class Action Commenced by the Firm - TMDX

April 4 at 8:30 PM | accessnewswire.com

TransMedics Group (NASDAQ:TMDX) Shares Up 7.4% - Here's Why

April 4 at 4:54 PM | marketbeat.com

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 15, 2025 in TransMedics Group, Inc. Lawsuit - TMDX

April 4 at 4:15 PM | accessnewswire.com

Levi & Korsinsky Reminds TransMedics Group, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 15, 2025 - TMDX

April 4 at 1:15 PM | accessnewswire.com

Scott+Scott Attorneys at Law LLP Reminds Investors of The Pending Class Action Against TransMedics Group, Inc. (TMDX)

April 4 at 12:53 PM | markets.businessinsider.com

Class Action Filed Against TransMedics Group, Inc. (TMDX) - April 15, 2025 Deadline to Join - Contact Levi & Korsinsky

April 4 at 11:00 AM | accessnewswire.com

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 15, 2025 in TransMedics Lawsuit - TMDX

April 4 at 10:25 AM | accessnewswire.com

Shareholders That Lost Money on TransMedics Group, Inc. (TMDX) Should Contact Levi & Korsinsky about pending Class Action - TMDX

April 4 at 8:00 AM | accessnewswire.com

TMDX SECURITIES ALERT: TransMedics Group Investors that Suffered Losses are Reminded of the Pending Class Action - Contact BFA Law before April 15 Legal Deadline

April 4 at 7:33 AM | accessnewswire.com

Shareholders of TransMedics Group, Inc. Should Contact Levi & Korsinsky Before April 15, 2025 to Discuss Your Rights - TMDX

April 4 at 7:25 AM | accessnewswire.com

TMDX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that TransMedics Group, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!

April 4 at 7:00 AM | accessnewswire.com

TransMedics Group, Inc. Sued for Securities Law Violations - Investors Should Contact Levi ...

April 4 at 6:12 AM | gurufocus.com

TransMedics Group, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 15, 2025 to Discuss Your Rights - TMDX

April 4 at 5:45 AM | prnewswire.com

TMDX SECURITIES: BFA Law Reminds TransMedics Group Investors with Losses to Contact the Firm before the April 15 Class Action Deadline

April 4 at 2:50 AM | markets.businessinsider.com

TransMedics Group (TMDX) Financial Success Faces Legal Scrutiny Amid Allegations - Hagens Berman

April 4 at 2:50 AM | markets.businessinsider.com

TransMedics Group, Inc. (NASDAQ:TMDX) Given Average Rating of "Moderate Buy" by Brokerages

April 4 at 2:36 AM | marketbeat.com

TMDX LAWSUIT ALERT: Levi & Korsinsky Notifies TransMedics Group, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

April 3 at 6:30 PM | accessnewswire.com

TMDX Investors Have Opportunity to Lead TransMedics Group Securities Fraud Lawsuit with Faruqi & Faruqi, LLP

April 3 at 6:10 PM | prnewswire.com

TMDX INVESTOR ALERT: TransMedics Group, Inc. ...

April 3 at 5:32 PM | gurufocus.com

Shareholders that lost money on TransMedics Group, Inc.(TMDX) should contact Levi & Korsinsky about pending Class Action - TMDX

April 3 at 4:30 PM | accessnewswire.com

TMDX INVESTOR ALERT: TransMedics Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit

April 3 at 4:05 PM | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BVS, NVST, TMDX, and ENOV Company Descriptions

Bioventus NYSE:BVS

$8.33 -0.82 (-8.96%)

Closing price 04/4/2025 04:00 PM Eastern

Extended Trading

$8.33 0.00 (0.00%)

As of 04/4/2025 04:20 PM Eastern

Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.

Enovis NYSE:ENOV

$32.52 -1.27 (-3.76%)

Closing price 04/4/2025 03:59 PM Eastern

Extended Trading

$32.53 +0.01 (+0.03%)

As of 04/4/2025 07:48 PM Eastern

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.

Envista NYSE:NVST

$15.47 -0.63 (-3.91%)

Closing price 04/4/2025 03:59 PM Eastern

Extended Trading

$15.48 +0.01 (+0.10%)

As of 04/4/2025 04:26 PM Eastern

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products. This segment also provides software packages, which include DTX Studio Implant; DTX Studio Lab; and DTX Studio Clinic, a software package offered with its imaging products. It offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.

TransMedics Group NASDAQ:TMDX

$67.67 -3.29 (-4.64%)

Closing price 04/4/2025 04:00 PM Eastern

Extended Trading

$66.75 -0.92 (-1.36%)

As of 04/4/2025 07:59 PM Eastern

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time